Axiom Investors’ Bradley Amoils is looking for only one kind of stock: a company changing dynamically, with sustainable growth, and trading at a reasonable valuation.
Amoils breaks the process down further: “About 60 per cent of our focus is on positive change and positive surprise.”“Twenty per cent is on the elements that are surprising, or sustainable, or growth that isn’t being identified by other people. And then the final 20 per cent is sort of a reality check, where you look at the valuation and some sanity check parameters to make sure that you’re not coming to the party way too late.
“My partner Andrew, who founded Axiom a couple years before I joined him, actually has a very similar background and he studied molecular biology at Princeton, and then went on to business school as well,” says Amoils. “The internet was very basic, and companies reported financial results in a very lagged fashion so by the time they reported the results, it was long-gone history."Picking winners
Despite his background in medicine, he admits it made very little difference when it came to examining the case for owning Moderna shares, which was simply the result of the same process Axiom uses for all its investments.